In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cosmetics national uniformity amendment pending introduction by Sen. Gregg.

This article was originally published in The Rose Sheet

Executive Summary

SENATE COSMETICS NATIONAL UNIFORMITY AMENDMENT PENDING introduction by Sen. Judd Gregg (R-N.H.) to Labor and Human Resources Committee Chairman Jim Jeffords' (R-Vt.) FDA reform legislation (S 830). Language in the uniformity amendment, which covers cosmetics and over-the-counter drugs, would give FDA regulatory precedent over state and local governments' safety and labeling statutes. The scope of FDA's preemption would also include any requirement concerning "public information or any other form of public communication relating to the safety or effectiveness of a drug or cosmetic," the proposed amendment states. "Public information" encompasses packaging information, advertising and promotional pieces such as shelf talkers and p-o-ps. The public information clause is an expansion of Gregg's 1996 amendment, which did not incorporate such language.



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts